CHARACTERIZING THE MECHANISM OF ACTION (MOA) OF INVESTIGATIONAL/APPROVED CANCER AGENTS

NCI癌症治疗和诊断部（DCTD）正在寻求支持，以开发在各种生化、细胞和体内系统中对已批准和正在研究的药物进行分子机制研究的能力。这种分子药理学能力将使NCI能够在细胞途径、肿瘤异质性、耐药性出现和免疫反应的背景下阐明药物作用机制（MOA）。该项目侧重于剖析药物治疗反应的分子途径，以阐明MOA，以推进NCI的临床前治疗研究。

The Division of Cancer Treatment and Diagnosis (DCTD), NCI, is requesting support to develop capability for performing molecular mechanistic studies of approved and investigational agents in various biochemical, cellular and in vivo systems. This molecular pharmacology capability will enable NCI to elucidate drug mechanisms of action (MOA) in the context of cellular pathways, tumor heterogeneity, emergence of drug resistance, and immunological response. This project focuses on dissecting molecular pathways in response to drug treatment to elucidate an MOA to advance pre-clinical therapeutic investigations by the NCI.